JP2005528921A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528921A5
JP2005528921A5 JP2004511543A JP2004511543A JP2005528921A5 JP 2005528921 A5 JP2005528921 A5 JP 2005528921A5 JP 2004511543 A JP2004511543 A JP 2004511543A JP 2004511543 A JP2004511543 A JP 2004511543A JP 2005528921 A5 JP2005528921 A5 JP 2005528921A5
Authority
JP
Japan
Prior art keywords
seq
patient
drug
level
fractalkine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004511543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528921A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/018570 external-priority patent/WO2003104484A1/en
Publication of JP2005528921A publication Critical patent/JP2005528921A/ja
Publication of JP2005528921A5 publication Critical patent/JP2005528921A5/ja
Withdrawn legal-status Critical Current

Links

JP2004511543A 2002-06-10 2003-06-10 Ｃｘ３ｃｒ１修飾物質を用いる糖尿病の治療および診断の方法 Withdrawn JP2005528921A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38769902P 2002-06-10 2002-06-10
PCT/US2003/018570 WO2003104484A1 (en) 2002-06-10 2003-06-10 Methods of treating and diagnosing diabetes with cx3cr1 modulators

Publications (2)

Publication Number Publication Date
JP2005528921A JP2005528921A (ja) 2005-09-29
JP2005528921A5 true JP2005528921A5 (https=) 2006-08-10

Family

ID=29736354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004511543A Withdrawn JP2005528921A (ja) 2002-06-10 2003-06-10 Ｃｘ３ｃｒ１修飾物質を用いる糖尿病の治療および診断の方法

Country Status (6)

Country Link
US (1) US20060160076A1 (https=)
EP (1) EP1511850A4 (https=)
JP (1) JP2005528921A (https=)
AU (1) AU2003243532A1 (https=)
CA (1) CA2487438A1 (https=)
WO (1) WO2003104484A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103684A2 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
EP2023144A1 (en) * 2007-08-01 2009-02-11 Sanofi-Aventis Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
AU2013226340B2 (en) 2012-02-27 2017-06-22 Ablynx N.V. CX3CR1-binding polypeptides
EP2820426A4 (en) * 2012-03-01 2015-07-29 Univ California NOVEL TARGET MOLECULE FOR THE DIAGNOSIS AND TREATMENT OF DIABETES AND HEART CIRCULAR DISEASES
WO2015026884A1 (en) * 2013-08-21 2015-02-26 Boehringer Ingelheim International Gmbh Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
CN103656639B (zh) * 2013-12-18 2015-02-18 南方医科大学南方医院 不规则趋化因子的中和抗体用于制备消除糖尿病心肾功能损害不良代谢记忆的药物的用途
MA46568A (fr) 2016-10-24 2019-08-28 Novo Nordisk As Dosage biologique de formulations d'insuline
WO2025264930A1 (en) * 2024-06-19 2025-12-26 The Trustees Of The University Of Pennsylvania Compositions and methods for immune cell trafficking modulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107475A (en) * 1992-11-17 2000-08-22 Icos Corporation Seven transmembrane receptors
CA2128208C (en) * 1992-11-17 2004-01-06 Ronald Godiska Novel seven transmembrane receptors
US6699677B1 (en) * 1999-12-20 2004-03-02 Chemocentryx, Inc. Tethered ligands and methods of use

Similar Documents

Publication Publication Date Title
Duric et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects
Straub et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression
Izumi et al. Effects of metoprolol on epinephrine-induced takotsubo-like left ventricular dysfunction in non-human primates
Vlassara Serum advanced glycosylation end products: A new class of uremic toxins?
JP2010031018A5 (https=)
Moser et al. Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial
Papadopoulos et al. Adiponectin and resistin plasma levels in healthy individuals with prehypertension
JP2006502702A5 (https=)
JP2005528921A5 (https=)
Lucarini et al. Involvement of vascular endothelial growth factor, CD44 and CD133 in periodontal disease and diabetes: an immunohistochemical study
CN105385774B (zh) Tmf1作为帕金森症诊断标志物的用途
Schopman et al. Effects of sitagliptin on counter‐regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double‐blind placebo‐controlled crossover study
Wu et al. SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross‐Sectional Study
Chidambaram et al. Replication of genome-wide association signals in Asian Indians with early-onset type 2 diabetes
CN112795645B (zh) 一种用于指导人高血糖用药的试剂盒
CN111925419B (zh) 一种多肽作为嗅觉受体Olfr109拮抗剂配体的应用
JP2009516155A5 (https=)
JP2005529603A5 (https=)
JP2005528080A5 (https=)
AU2018329850A1 (en) Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)
JP2007500005A5 (https=)
KR102935795B1 (ko) 유전자 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
KR20190083110A (ko) 마약 중독 또는 금단증상 진단용 바이오마커 조성물 및 마약 중독 또는 금단증상 진단용 키트
JP2006500002A5 (https=)
Song et al. Improvement of Glycosylated Hemoglobin in Patients with Type 2 Diabetes Mellitus under Insulin Treatment by Reimbursement for Self-Monitoring of Blood Glucose.